The board recommended distributing cash dividends of SAR 400 million to shareholders for the year 2024, at SAR 2 per share, equivalent to 20 percent of the nominal value.
Compare that to the prior year:
for 2023, the board recommended SAR 350 million in cash dividends, at SAR 1.75 per share, equivalent to 17.5 percent of the nominal value.
The Mouwasat Medical dividends 2024 payout represented a meaningful step-up, signaling that management is confident enough in the underlying cash generation to return more capital even as it funds a multi-year expansion program.
For the second half of 2025, the board recommended SAR 225 million in dividends, representing 11.25 percent of capital, at SAR 1.12 per share for 200 million eligible shares.
The H2 figure, combined with the SAR 200 million paid for H1 2025, puts the full-year 2025 dividend payout at SAR 425 million, a further escalation that speaks to balance sheet confidence rather than capital conservation.
Leverage, at 20.6 percent debt-to-capital, remained well controlled.
The structural context behind these numbers is Vision 2030's healthcare privatization mandate.
The healthcare sector in Saudi Arabia has seen rising demand driven by population growth, an expanding working-age demographic, and higher rates of chronic disease awareness, while Vision 2030's health transformation objectives have resulted in increased government support for private sector healthcare providers and greater emphasis on preventive care, specialized medicine, and patient-centered services.
For Mouwasat, this translates directly into a growing insured patient base.
Its patient base spans a broad demographic, including insured private sector employees, Saudi nationals, and expatriate residents who increasingly access private healthcare through employer-sponsored insurance plans.
Insurance penetration is the revenue engine underneath the quarterly results, and its direction remains firmly upward.
Now set Mouwasat against its Riyadh-based peer, Dallah Health, and the sector picture sharpens considerably. The Dallah Health IPO valuation analysis that circulated at the time of its listing framed the company as a premium Riyadh operator with a concentrated geographic footprint and a high-growth bed expansion story.
Today, Dallah owns six healthcare facilities, including Dallah Al Nakheel and Namar Hospitals, Dallah Clinics, and Dallah Homecare, and in 2023 the company treated more than 2.5 million patients.
Dallah's trailing price-to-earnings ratio stands at approximately 21 times, with a forward PE of around 18.7 times.
Return on equity is 13.74 percent and return on invested capital is 7.52 percent.
Those ROIC figures are instructive. A capital-intensive hospital expansion cycle compresses returns in the near term, and both Mouwasat and Dallah are navigating exactly that compression simultaneously. The question for investors evaluating either name is not whether the growth thesis is valid. It clearly is. The question is how long the ramp-up period lasts and whether the margin recovery, when it arrives, is durable or episodic.
Mouwasat's 40 percent capacity expansion plan, along with the costs associated with that build, drives revenue and net income forecast CAGRs of 10.7 percent and 15.3 percent respectively through FY29.
If those forecasts prove accurate, the current earnings trajectory is a mid-cycle trough in profitability relative to what the installed capacity will eventually produce. The Mouwasat Medical Services quarterly results, read in sequence, tell that story with reasonable consistency. Revenue is accelerating. Margins are under managed pressure, not structural pressure. And the dividend escalation confirms that free cash flow is real, not cosmetic.
The investor-relevant takeaway is this: the Saudi private hospital sector is in a capital deployment phase, not a capital return phase, and the quarterly earnings of its leading operators will continue to reflect that tension for the next several reporting periods. The companies that emerge from this cycle with the strongest occupancy ramp and the cleanest cost absorption will command a meaningful re-rating. Mouwasat's earnings trajectory, imperfect as it looks quarter to quarter, suggests it is building toward exactly that outcome.
For informational and research purposes only. This is analysis and research, not a solicitation to buy or sell any security. Consult a licensed financial advisor before making any investment decision.
